Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

StarTric - A novel transcatheter medical device to treat Tricuspid Regurgitation

Objective

"Tricuspid Regurgitation (TR) poses a significant health challenge, affecting millions worldwide. Current treatment options, primarily open-heart surgery, come with inherent risks and are often unsuitable for frail patients. StarTric has pioneered a transcatheter device tailored to the intricate task of addressing TR. Drawing inspiration from the highly successful open-heart ""clover"" technique, this innovative device offers a minimally invasive alternative for TR repair. The StarTric device will reshape the tricuspid valve into a clover-like configuration, effectively restoring proper valve function. By replicating the efficacy of the clover procedure through transcatheter means, StarTric's solution holds immense promise in transforming the lives of countless patients globally. To bring this breakthrough solution to patients in need, StarTric requires funding support to accelerate development, clinical trials, regulatory approval and commercial efforts."

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-EIC-ACC - HORIZON EIC Accelerator

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-EIC-2024-ACCELERATOR-02

See all projects funded under this call

Coordinator

STAR TRIC SRL
Net EU contribution
€ 2 499 999,00
Address
Via della Moscova , 3 - 20121
20121 Milano
Italy
SME
Yes
Region
Nord-Ovest Lombardia Milano
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
No data